Treatment of Bone Tumors

Surgical Pathology Clinics

Volumn 5, Issue 1, 2012, Pages 301-318

  Rajani, Rajiv ^a   Gibbs, C Parker ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone tumor; Chondrosarcoma; Ewing sarcoma; Osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

BONE TUMOR; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHONDROSARCOMA; EWING SARCOMA; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY;

EID: 84856657188     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2011.07.015     Document Type: Review

References (106)

1. Gibbs C.P., Weber K., Scarborough M.T. Malignant bone tumors. Instr Course Lect 2002, 51:413-428.
2. Meyers P.A., Schwartz C.L., Krailo M., et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. JClin Oncol 2005, 23(9):2004-2011.
3. Jaffe N., Carrasco H., Raymond K., et al. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?. Cancer 2002, 95(10):2202-2210.
4. Chi S.N., Conklin L.S., Qin J., et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2004, 42(1):46-51.
5. Wuisman P., Enneking W.F. Prognosis for patients who have osteosarcoma with skip metastasis. JBone Joint Surg Am 1990, 72(1):60-68.
6. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003, 145(1):1-30.
7. Miller C.W., Aslo A., Won A., et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. JCancer Res Clin Oncol 1996, 122(9):559-565.
8. Feugeas O., Guriec N., Babin-Boilletot A., et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. JClin Oncol 1996, 14(2):467-472.
9. Siddiqui N.H., Jani J. Osteosarcoma metastatic to adrenal gland diagnosed by fine-needle aspiration. Diagn Cytopathol 2005, 33(3):201-204.
10. Ragland B.D., Bell W.C., Lopez R.R., et al. Cytogenetics and molecular biology of osteosarcoma. Lab Invest 2002, 82(4):365-373.
11. Gibbs C.P., Kukekov V.G., Reith J.D., et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005, 7(11):967-976.
12. Wu C., Wei Q., Utomo V., et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007, 67(17):8216-8222.
13. Levings P.P., McGarry S.V., Currie T.P., et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009, 69(14):5648-5655.
14. Stokkel M.P., Linthorst M.F., Borm J.J., et al. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. JCancer Res Clin Oncol 2002, 128(7):393-399.
15. Costelloe C.M., Macapinlac H.A., Madewell J.E., et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. JNucl Med 2009, 50(3):340-347.
16. Okada K., Frassica F.J., Sim F.H., et al. Parosteal osteosarcoma. A clinicopathological study. JBone Joint Surg Am 1994, 76(3):366-378.
17. Schwab J.H., Antonescu C.R., Athanasian E.A., et al. Acomparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res 2008, 466(6):1318-1322.
18. Eilber F.R., Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol 1989, 16(4):312-322.
19. Link M.P., Goorin A.M., Miser A.W., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. NEngl J Med 1986, 314(25):1600-1606.
20. Ferrari S., Smeland S., Mercuri M., et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. JClin Oncol 2005, 23(34):8845-8852.
21. Glasser D.B., Lane J.M., Huvos A.G., et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 1992, 69(3):698-708.
22. Zhou Q., Deng Z., Zhu Y., et al. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 2010, 27(4):1239-1245.
23. Vemulapalli S., Mita A., Alvarado Y., et al. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol 2011, 6(1):29-39.
24. Mita M.M., Mita A.C., Chu Q.S., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. JClin Oncol 2008, 26(3):361-367.
25. Moriceau G., Ory B., Mitrofan L., et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 2010, 70(24):10329-10339.
26. Cirocchi R., Farinella E., La Mura F., et al. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review. Tumori 2010, 96(3):392-399.
27. Scotlandi K., Picci P., Kovar H. Targeted therapies in bone sarcomas. Curr Cancer Drug Targets 2009, 9(7):843-853.
28. Ahmed S.F., Farquharson C. The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins. JEndocrinol 2010, 206(3):249-259.
29. Scotlandi K., Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008, 20(4):419-427.
30. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50(6):1190-1197.
31. Kurmasheva R.T., Dudkin L., Billups C., et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009, 69(19):7662-7671.
32. Meyers P.A., Schwartz C.L., Krailo M.D., et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. JClin Oncol 2008, 26(4):633-638.
33. Chou A.J., Kleinerman E.S., Krailo M.D., et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009, 115(22):5339-5348.
34. Shin K.H., Rougraff B.T., Simon M.A. Oncologic outcomes of primary bone sarcomas of the pelvis. Clin Orthop Relat Res 1994, (304):207-217.
35. Brien E.W., Mirra J.M., Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Skeletal Radiol 1997, 26(6):325-353.
36. Bruns J., Elbracht M., Niggemeyer O. Chondrosarcoma of bone: an oncological and functional follow-up study. Ann Oncol 2001, 12(6):859-864.
37. Tiet T.D., Hopyan S., Nadesan P., et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006, 168(1):321-330.
38. Schrage Y.M., Lam S., Jochemsen A.G., et al. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth invitro. JCell Mol Med 2009, 13(9A):2843-2852.
39. Larramendy M.L., Tarkkanen M., Valle J., et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997, 150(2):685-691.
40. van Beerendonk H.M., Rozeman L.B., Taminiau A.H., et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. JPathol 2004, 202(3):359-366.
41. Okada T., Tanaka K., Nakatani F., et al. Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer 2006, 118(1):90-97.
42. Sakimura R., Tanaka K., Yamamoto S., et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007, 13(1):275-282.
43. Marco R.A., Gitelis S., Brebach G.T., et al. Cartilage tumors: evaluation and treatment. JAm Acad Orthop Surg 2000, 8(5):292-304.
44. Murphey M.D., Flemming D.J., Boyea S.R., et al. Enchondroma versus chondrosarcoma in the appendicular skeleton: differentiating features. Radiographics 1998, 18(5):1213-1237. [quiz: 1244-5].
45. Feldman F., Van Heertum R., Saxena C., et al. 18FDG-PET applications for cartilage neoplasms. Skeletal Radiol 2005, 34(7):367-374.
46. Brenner W., Conrad E.U., Eary J.F. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004, 31(2):189-195.
47. Jamil N., Howie S., Salter D.M. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol 2010, 91(5):387-393.
48. Nguyen Q.N., Chang E.L. Emerging role of proton beam radiation therapy for chordoma and chondrosarcoma of the skull base. Curr Oncol Rep 2008, 10(4):338-343.
49. Wyman J.J., Hornstein A.M., Meitner P.A., et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and invitro chemoresistance. JOrthop Res 1999, 17(6):935-940.
50. Terek R.M., Healey J.H., Garin-Chesa P., et al. p53 mutations in chondrosarcoma. Diagn Mol Pathol 1998, 7(1):51-56.
51. Mitchell A.D., Ayoub K., Mangham D.C., et al. Experience in the treatment of dedifferentiated chondrosarcoma. JBone Joint Surg Br 2000, 82(1):55-61.
52. Dickey I.D., Rose P.S., Fuchs B., et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. JBone Joint Surg Am 2004, 86(11):2412-2418.
53. Grimer R.J., Gosheger G., Taminiau A., et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 2007, 43(14):2060-2065.
54. Workman P., Burrows F., Neckers L., et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216.
55. Hollingshead M., Alley M., Burger A.M., et al. Invivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005, 56(2):115-125.
56. Trepel J., Mollapour M., Giaccone G., et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10(8):537-549.
57. Pacey S., Wilson R.H., Walton M., et al. Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011, 17(6):1561-1570.
58. David E., Guihard P., Brounais B., et al. Direct anti-cancer effect of oncostatin M on chondrosarcoma. Int J Cancer 2011, 128(8):1822-1835.
59. Herbst R.S., Eckhardt S.G., Kurzrock R., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. JClin Oncol 2010, 28(17):2839-2846.
60. Mohler D.G., Chiu R., McCall D.A., et al. Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function. Clin Orthop Relat Res 2010, 468(10):2765-2773.
61. Donati D., Colangeli S., Colangeli M., et al. Surgical treatment of grade I central chondrosarcoma. Clin Orthop Relat Res 2010, 468(2):581-589.
62. Bruns J., Fiedler W., Werner M., et al. Dedifferentiated chondrosarcoma-a fatal disease. JCancer Res Clin Oncol 2005, 131(6):333-339.
63. Franchi A., Pasquinelli G., Cenacchi G., et al. Immunohistochemical and ultrastructural investigation of neural differentiation in Ewing sarcoma/PNET of bone and soft tissues. Ultrastruct Pathol 2001, 25(3):219-225.
64. Taylor C., Patel K., Jones T., et al. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation. Br J Cancer 1993, 67(1):128-133.
65. Zwerner J.P., Guimbellot J., May W.A. EWS/FLI function varies in different cellular backgrounds. Exp Cell Res 2003, 290(2):414-419.
66. Riggi N., Suva M.L., Suva D., et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008, 68(7):2176-2185.
67. Kinsey M., Smith R., Lessnick S.L. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006, 4(11):851-859.
68. Toomey E.C., Schiffman J.D., Lessnick S.L. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 2010, 29(32):4504-4516.
69. Kovar H. Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr Opin Oncol 1998, 10(4):334-342.
70. Staege M.S., Hutter C., Neumann I., et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004, 64(22):8213-8221.
71. Hu-Lieskovan S., Zhang J., Wu L., et al. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 2005, 65(11):4633-4644.
72. Lessnick S.L., Dacwag C.S., Golub T.R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002, 1(4):393-401.
73. Rorie C.J., Thomas V.D., Chen P., et al. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 2004, 64(4):1266-1277.
74. Castillero-Trejo Y., Eliazer S., Xiang L., et al. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005, 65(19):8698-8705.
75. Miyagawa Y., Okita H., Nakaijima H., et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008, 28(7):2125-2137.
76. Tirode F., Laud-Duval K., Prieur A., et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11(5):421-429.
77. Lemmi M.A., Fletcher B.D., Marina N.M., et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. AJR Am J Roentgenol 1990, 155(2):343-346.
78. Hawkins D.S., Schuetze S.M., Butrynski J.E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. JClin Oncol 2005, 23(34):8828-8834.
79. Rodriguez-Galindo C., Navid F., Liu T., et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol 2008, 19(4):814-820.
80. Esiashvili N., Goodman M., Marcus R.B. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. JPediatr Hematol Oncol 2008, 30(6):425-430.
81. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. NEngl J Med 2003, 348(8):694-701.
82. Picci P., Rougraff B.T., Bacci G., et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. JClin Oncol 1993, 11(9):1763-1769.
83. Wunder J.S., Paulian G., Huvos A.G., et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. JBone Joint Surg Am 1998, 80(7):1020-1033.
84. Bacci G., Forni C., Longhi A., et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004, 40(1):73-83.
85. Bacci G., Longhi A., Briccoli A., et al. The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65(3):766-772.
86. Oberlin O., Deley M.C., Bui B.N., et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001, 85(11):1646-1654.
87. Sluga M., Windhager R., Lang S., et al. The role of surgery and resection margins in the treatment of Ewing's sarcoma. Clin Orthop Relat Res 2001, (392):394-399.
88. Laskar S., Mallick I., Gupta T., et al. Post-operative radiotherapy for Ewing sarcoma: when, how and how much?. Pediatr Blood Cancer 2008, 51(5):575-580.
89. Indelicato D.J., Keole S.R., Shahlaee A.H., et al. Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys 2008, 72(3):871-877.
90. Shi W., Indelicato D.J., Keole S.R., et al. Radiation treatment for Ewing family of tumors in adults: the University of Florida experience. Int J Radiat Oncol Biol Phys 2008, 72(4):1140-1145.
91. Indelicato D.J., Keole S.R., Shahlaee A.H., et al. Impact of local management on long-term outcomes in Ewing tumors of the pelvis and sacral bones: the University of Florida experience. Int J Radiat Oncol Biol Phys 2008, 72(1):41-48.
92. Davis A.M., O'Sullivan B., Turcotte R., et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005, 75(1):48-53.
93. Erkizan H.V., Kong Y., Merchant M., et al. Asmall molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009, 15(7):750-756.
94. Mateo-Lozano S., Tirado O.M., Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003, 22(58):9282-9287.
95. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005, 65(19):8984-8992.
96. Yee D., Favoni R.E., Lebovic G.S., et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. JClin Invest 1990, 86(6):1806-1814.
97. Benini S., Manara M.C., Baldini N., et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001, 7(6):1790-1797.
98. Toretsky J.A., Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 2010, 11(2):105-106.
99. Buck E., Gokhale P.C., Koujak S., et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010, 9(10):2652-2664.
100. Garofalo C., Manara M.C., Nicoletti G., et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011, 30(24):2730-2740.
101. Salazar R., Reidy-Lagunes D., Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 2011, 71(7):841-852.
102. Ordonez J.L., Osuna D., Herrero D., et al. Advances in Ewing's sarcoma research: where are we now and what lies ahead?. Cancer Res 2009, 69(18):7140-7150.
103. Sohn H.W., Choi E.Y., Kim S.H., et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. Am J Pathol 1998, 153(6):1937-1945.
104. Scotlandi K., Baldini N., Cerisano V., et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000, 60(18):5134-5142.
105. Rocchi A., Manara M.C., Sciandra M., et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. JClin Invest 2010, 120(3):668-680.
106. Cho H.M., Rosenblatt J.D., Tolba K., et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010, 70(24):10121-10130.